Arcturus Therapeutics
ARCT
156 hedge funds and large institutions have $909M invested in Arcturus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 16 closing their positions.
113% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 16
65% more call options, than puts
Call options by funds: $22.8M | Put options by funds: $13.8M
31% more capital invested
Capital invested by funds: $694M → $909M (+$215M)
14% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 42
12% more funds holding
Funds holding: 139 → 156 (+17)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.5% less ownership
Funds ownership: 77.91% → 72.41% (-5.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.4M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$6.44M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$6.44M |
| 4 |
Millennium Management
New York
|
+$3.99M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$3.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$28.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$15.9M |
| 3 |
Two Sigma Investments
New York
|
-$14.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.8M |
| 5 |
Two Sigma Advisers
New York
|
-$10.8M |
ARCT Hedge Fund Activity: Q3 2021 in Review
156 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2021, worth a combined $909M — up 31% from $694M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ARCT positions and 16 closed out — a net gain of 18 holders — while 48 added to existing stakes and 42 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $15.4M. The largest seller was OrbiMed, exiting entirely with an estimated $28.7M sold.
- 156 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2021, up from 139 in Q2 2021.
- Funds reported $909M of Arcturus Therapeutics stock for Q3 2021, up 31% quarter-over-quarter.
- 34 funds opened new Arcturus Therapeutics positions in Q3 2021 and 16 closed out, a net change of +18 holders.
- The largest Arcturus Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $15.4M added.
- The largest Arcturus Therapeutics seller in Q3 2021 was OrbiMed, an estimated $28.7M sold.
Based on aggregated 13F filings for Q3 2021.